FDA rejects Pozen's omeprazole/aspirin combo tablets; shares tumble
This article was originally published in Scrip
Executive Summary
Shares of Pozen tumbled 28.4% in morning trading on 28 April on word the FDA rejected the company's new drug application (NDA) to market its combination immediate-release generic omeprazole and enteric-coated (EC) delayed-release aspirin tablets, dubbed PA8140 and PA32540.